MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

33.89
+0.40
+1.19%
After Hours: 34.39 +0.5 +1.48% 16:58 09/17 EDT
OPEN
33.72
PREV CLOSE
33.49
HIGH
34.45
LOW
32.64
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
34.45
52 WEEK LOW
14.71
MARKET CAP
2.83B
P/E (TTM)
-15.0837
1D
5D
1M
3M
1Y
5Y
Insider Sell: Cytokinetics
MT Newswires · 17h ago
Cytokinetics Announces Results From REDWOOD-HCM and GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression to Phase 3 Clinical Trial
GlobeNewswire · 5d ago
Cytokinetics to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in the following investor conferences in Septe...
GlobeNewswire · 09/08 20:00
Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Eastern Time to discuss the full results from REDWOOD-HCM ...
GlobeNewswire · 09/07 11:30
Spinal Muscular Atrophy Treatment Market Key Players, Industry Overview and Forecasts to 2028
Research Nester published a report titled  which delivers a detailed overview of the Spinal muscular atrophy drug market in terms of market segmentation by treatment, by route of administration, by disease type,  and by region.
AmericaNewsHour · 09/06 07:24
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2021 it granted stock options to purchase an aggregate of 113,600 shares of common stock to 10 new employees, whose...
GlobeNewswire · 09/01 20:00
New Strong Sell Stocks for August 31st
Zacks.com · 08/31 13:07
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Benzinga · 08/31 12:05
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTK. Analyze the recent business situations of Cytokinetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTK stock price target is 45.30 with a high estimate of 58.00 and a low estimate of 33.00.
EPS
Institutional Holdings
Institutions: 257
Institutional Holdings: 77.98M
% Owned: 93.38%
Shares Outstanding: 83.51M
TypeInstitutionsShares
Increased
68
7.65M
New
19
2.40M
Decreased
66
7.00M
Sold Out
22
2.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Leonard Gage
Chief Executive Officer/President/Director
Robert Blum
Chief Financial Officer/Senior Vice President
Ching Jaw
Chief Human Resource Officer/Chief Administrative Officer
David Cragg
Executive Vice President
Andrew Callos
Executive Vice President
Fady Malik
Senior Vice President/General Counsel/Secretary
Mark Schlossberg
Independent Director
Muna Bhanji
Independent Director
Robert Califf
Independent Director
Santo Costa
Independent Director
John Henderson
Independent Director
Edward Kaye
Independent Director
B. Lynne Parshall
Independent Director
Sandford Smith
Independent Director
Wendell Wierenga
Independent Director
Nancy Wysenski
No Data
  • All
  • Financials
  • Insiders
More
About CYTK
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.